AtaiBeckley ATAI
NASDAQ ATAI
$7.39 +0.05 (+0.68%)
As of: Sep 4, 2026 · 3:59 PM EDT

AtaiBeckley (ATAI) Cash from Investing Activities (2020 - 2026)

AtaiBeckley (ATAI) posted quarterly Cash from Investing Activities of -$21.7 million for Q1 2026, down 96.6% year-over-year from -$636.0 million in Q1 2025, and down 96.6% quarter-over-quarter from -$11.0 million in Q1 2025.

Analysis

AtaiBeckley (ATAI) Cash from Investing Activities (2020 - 2026) Analysis & Trends

AtaiBeckley has reported Cash from Investing Activities for 6 years, with the latest figure at -$67.6 million in Q3 2025.

  • Quarterly Cash from Investing Activities fell 371.95% year-over-year to -$67.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$62.2 million (down 220.15% YoY) and the FY2024 annual result came in at $59.2 million, up 211.03% from the prior year.
  • Cash from Investing Activities for Q1 2026 stood at -$21.7 million, down from -$11.0 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was -$11.0 million in Q1 2025, with the low at -$21.7 million in Q1 2026.
  • A 5-year average of -$12.2 million and a median of -$823000.0 in 2023 frame the typical range for Cash from Investing Activities.
  • The widest YoY moves for Cash from Investing Activities: up 10857.33% in 2022, down 5670.92% in 2022.
  • Over 5 years, Cash from Investing Activities stood at -$48.6 million in 2021, then jumped by 264.6% to $80.1 million in 2022, then slumped by 101.03% to -$823000.0 in 2023, then surged by 897.08% to $6.6 million in 2024, then plunged by 1129.77% to -$67.6 million in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods registered -$67.6 million, $9.8 million, and -$11.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -45.80 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -92.70 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 329.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -1.66 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -49.35 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -363.46 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -229.72 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 24.51 Mn
10 AtaiBeckley 1.61 Bn 1.61 Bn - -67.55 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 158.59 Mn
Mar 31, 2026 -21.65 Mn
Sep 30, 2025 -67.55 Mn
Jun 30, 2025 9.78 Mn
Jun 30, 2025 9.78 Mn
Mar 31, 2025 -11.01 Mn
Mar 31, 2025 -11.01 Mn
Dec 31, 2024 6.56 Mn
Sep 30, 2024 24.84 Mn
Jun 30, 2024 16.30 Mn
Mar 31, 2024 11.47 Mn
Dec 31, 2023 -823,000.00
Sep 30, 2023 -46.49 Mn
Jun 30, 2023 -22.01 Mn
Mar 31, 2023 16.02 Mn
Dec 31, 2022 80.05 Mn
Sep 30, 2022 66.05 Mn
Jun 30, 2022 -18.21 Mn
Mar 31, 2022 -214.74 Mn
Dec 31, 2021 -48.63 Mn